

Public Health Key Documents: February 2022

NIHR

Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review

The RCT and review showed that performing endometrial scratch prior to the first cycle of IVF did not increase live birth rates compared with IVF without this procedure

Systematic search: Yes

February 2022

<https://www.journalslibrary.nihr.ac.uk/hta/JNzt9406/>

Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis

Evidence was insufficient to make a full assessment of the role and economic value of the biomarkers being considered for use in acute kidney injury.

Systematic search: Yes

February 2022

<https://www.journalslibrary.nihr.ac.uk/hta/UGEZ4120/>

The King's Fund

What is compassionate leadership?

Compassionate leadership involves a focus on relationships through careful listening to, understanding, empathising with and supporting other people, enabling those we lead to feel valued, respected and cared for, so they can reach their potential and do their best work.

Compassionate leadership results in more engaged and motivated staff with high levels of wellbeing, who produce high-quality care.

Systematic search: No

February 2022

<https://www.kingsfund.org.uk/publications/what-is-compassionate-leadership>

Scottish Medicines Consortium (SMC Advice)

nivolumab (Opdivo®)

Accepted for use in combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).

Systematic search: No

February 2022

<https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-full-smc2385/>

enzalutamide (Xtandi®)

Accepted for use treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).

Systematic search: No

February 2022

<https://www.scottishmedicines.org.uk/medicines-advice/enzalutamide-xtandi-full-smc2400/>

pemigatinib (Pemazyre®)

Accepted for use for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Systematic search: No

February 2022

<https://www.scottishmedicines.org.uk/medicines-advice/pemigatinib-pemazyre-full-smc2399/>

cannabidiol (Epidyolex®)

Accepted for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.

Systematic search: No

February 2022

<https://www.scottishmedicines.org.uk/medicines-advice/cannabidiol-epidyolex-tsc-full-smc2402/>

cenobamate (Ontozry®)

Accepted for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products

Systematic search: No

February 2022

<https://www.scottishmedicines.org.uk/medicines-advice/cenobamate-ontozry-full-smc2408/>

diroximel fumarate (Vumerity®)

Accepted for use for the treatment of adult patients with relapsing remitting multiple sclerosis.

Systematic search: No

February 2022

<https://www.scottishmedicines.org.uk/medicines-advice/diroximel-fumarate-vumerity-abb-smc2444/>

risdiplam (Evrysdi®)

Accepted for use for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 [survival of motor neuron 2] copies.

Systematic search: No

February 2022

<https://www.scottishmedicines.org.uk/medicines-advice/risdiplam-evrysdi-full-smc2401/>

Scottish Government

Life at age 14: initial findings from the Growing Up in Scotland study

The report is based on data collected in 2019/20 and presents high level findings relating to young people's experiences across a range of life domains.

Systematic search: No

February 2022

<https://www.gov.scot/publications/life-age-14-initial-findings-growing-up-scotland-study/>

National Care Service: consultation analysis

Systematic search: No

February 2022

<https://www.gov.scot/publications/national-care-service-consultation-analysis-responses/documents/>

Connecting Scotland - evaluation: qualitative research - implementation and early impact

Findings of research with organisations who applied for digital devices, through the Connecting Scotland programme, to distribute to people that they support.

Systematic search: No

February 2022

<https://www.gov.scot/publications/evaluation-connecting-scotland-qualitative-research-key-stakeholders-exploring-implementation-early-impact/>

SIGN

Nil

Public Health Scotland

Alcohol sales and harm in Scotland during the COVID-19 pandemic

Population-level alcohol consumption in Scotland was lower following the start of the COVID-19 pandemic than in 2017–19. While alcohol-related hospital stays decreased during the pandemic for some population groups, alcohol-specific deaths also increased for these groups. These same groups already had among the highest alcohol-specific death rates before the pandemic. Increased rates of alcohol-specific death for some groups may support existing evidence that drinking at hazardous and harmful levels may have increased for some groups, despite consumption reducing at the population level. Of concern is the potential that groups with high levels of alcohol consumption before the pandemic may have increased their alcohol consumption, had reduced access to hospital treatment for alcohol-related conditions, and potentially experienced higher rates of mortality as a consequence. Tackling alcohol consumption and harms, particularly among high-risk groups, should be a critical objective of any COVID-19 recovery plans

Systematic search: No

February 2022

<https://www.publichealthscotland.scot/publications/alcohol-sales-and-harm-in-scotland-during-the-covid-19-pandemic/>

NICE – Guidelines

Nil

NICE - Technology Appraisal Guidance

TA772 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies

Systematic search: Yes

February 2022

<https://www.nice.org.uk/guidance/ta772>

TA770 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer

Systematic search: Yes

February 2022

<https://www.nice.org.uk/guidance/ta770>

TA763 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable

Systematic search: Yes

February 2022

<https://www.nice.org.uk/guidance/ta763>

TA764 Fremanezumab for preventing migraine

Systematic search: Yes

February 2022

<https://www.nice.org.uk/guidance/ta764>

TA765 Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

Systematic search: Yes

February 2022

<https://www.nice.org.uk/guidance/ta765>

TA766 Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma

Systematic search: Yes

February 2022

<https://www.nice.org.uk/guidance/ta766>

TA767 Ponesimod for treating relapsing–remitting multiple sclerosis

Systematic search: Yes

February 2022

<https://www.nice.org.uk/guidance/ta767>

TA768 Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

Systematic search: Yes

February 2022

<https://www.nice.org.uk/guidance/ta768>

TA769 Palforzia for treating peanut allergy in children and young people

Systematic search: Yes

February 2022

<https://www.nice.org.uk/guidance/ta769>

EPPI Centre

Nil

AHRQ (Agency for Healthcare Research and Quality – USA)

Nil

Health Foundation

Addressing the leading risk factors for ill health

A review of government policies tackling smoking, poor diet, physical inactivity and harmful alcohol use in England

Systematic search: No

February 2022

<https://www.health.org.uk/publications/reports/addressing-the-leading-risk-factors-for-ill-health>

Canadian Agency for drugs and Technologies in Health (CADTH)

Temperature Management in Patients After Cardiac Arrest

Two systematic reviews, one RCT and seven non-randomized studies compared the clinical effectiveness of normothermia versus hypothermia in adult patients after cardiac arrest. Normothermia was found to be similar to hypothermia for several clinical- and patient related outcomes, such as survival, hospital mortality, and quality of life. There was limited evidence to suggest that either type of targeted temperature management was more effective, with findings suggesting that normothermia may be associated with greater protocol adherence and decreased prescription medication use coming from low-quality non-randomized studies. Four evidence-based guidelines were identified which strongly recommend targeted temperature management for eligible patients, particularly for patients resuscitated following out-of-hospital cardiac arrest. Guidelines from the Canadian Cardiovascular Society and American Academy of Neurology present strong recommendations for hypothermic targeted temperature management.

Systematic search: Limited

February 2022

<https://www.cadth.ca/temperature-management-patients-post-cardiac-arrest>

Antibiotic Solutions for Surgical Irrigation

20 different antibiotic solutions were identified. Most studies showed that antibiotic irrigation solutions were better or no different compared to using antiseptic, saline, or no irrigation but a small number of studies indicated otherwise. One study reported in a systematic review showed fewer infections and complications for antiseptic compared to a triple antibiotic solution, while another study included in the same systematic review found a higher percentage of implant loss when a triple antibiotic solution was compared to antiseptic although data were poorly reported in these studies. Bacitracin-specific evidence was found in two studies; one study showed a higher percentage of infection when bacitracin irrigation was compared to cefazolin and saline irrigation; however, this was not statistically significant. Another study showed no differences in infections requiring surgical intervention or in hospitalization when bacitracin irrigation was compared to no irrigation. One guideline recommends that wound irrigation and intracavity lavage should not be conducted during surgery, and that applying antibiotics before wound closure should only be done as part of a research trial. High-quality research is needed to clarify the role of antibiotic irrigation during surgery. Updated guidelines to include research from more current studies are also needed.

Systematic search: Limited

February 2022

<https://www.cadth.ca/antibiotic-solutions-surgical-irrigation-0>

Custom-Made Foot Orthotics for People with Lower Limb Conditions

There were no statistically significant differences between custom-made foot orthotics and prefabricated foot orthotics for plantar heel pain in adults. There is limited evidence for short-term pain relief and improved quality of life with custom-made orthotics compared to placebo or no intervention in adults with plantar fasciitis. Custom-made foot orthotics are less cost-effective than other interventions (placebo, prefabricated orthotics, usual care) in the short and medium term. Two evidence-based guidelines recommended the use of custom-made foot orthotics in patients with diabetes for prevention and treatment of foot ulceration.

Systematic search: Limited

February 2022

<https://www.cadth.ca/custom-made-foot-orthotics-people-lower-limb-conditions>

McGill University Health Centre (Canada)

Nil

Health Information & Quality Authority (Ireland) – Health Technology Assessments

Nil

Campbell Collaboration

Nil

Glasgow Centre for Population Health

Nil

NICE FORWARD PLANNING – Publications due March 2022

Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies

Single Technology Appraisal

Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

Social Care

Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis

Single Technology Appraisal

Mental wellbeing at work

Public health guideline

Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer

Single Technology Appraisal

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies

Single Technology Appraisal

Dapagliflozin for treating chronic kidney disease

Single Technology Appraisal

Otitis media (acute): antimicrobial prescribing (update)

Antimicrobial prescribing guideline

Integrated health and social care for people experiencing homelessness

Public health guideline

Hypertension in adults: diagnosis and management (update)

Clinical Guideline

Neonatal parenteral nutrition

Quality Standard

Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in adults with elevated triglycerides

Single Technology Appraisal

Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations

Single Technology Appraisal

Fenfluramine for treating Dravet syndrome

Single Technology Appraisal

Joint replacement (primary): hip, knee and shoulder

Quality Standard

Semaglutide for managing overweight and obesity

Single Technology Appraisal

MT476 UroShield for preventing catheter-associated urinary tract infections

Medical Technology

Diabetes (type 1 and type 2) in children and young people: diagnosis and management – glucose monitoring

Clinical Guideline

Type 1 diabetes in adults: diagnosis and management – glucose monitoring and diagnosis

Clinical Guideline

Type 2 diabetes in adults: management – glucose monitoring

Clinical Guideline